Ocular Therapeutix, Inc. (OCUL) Cash Flow Statement

The gap between net income and operating cash flow is modest but persistent, with OCF/NI ratios below 1.0 in most quarters, suggesting that non-cash charges like SBC and D&A are partially offset by working capital outflows. The negative working capital changes in several quarters, such as -$5.0M in 2026Q2, imply that cash is being consumed by operational needs beyond the reported loss. This pattern is typical for a clinical-stage biotech scaling R&D, but the consistency of the gap warrants monitoring for any deterioration in cash conversion efficiency.

The FCF trajectory shows a clear inflection point around 2024Q1, coinciding with the strategic pivot to retina, and has since steepened. Quarterly FCF burn has roughly doubled from the mid-$30M range to over $70M, driven primarily by operating losses rather than capex, which remains modest. This suggests the company is in a deliberate investment phase, but the accelerating burn rate implies a finite runway that investors should track against the $737M cash balance.

Capex is not a meaningful cash outflow for OCUL, as the company appears to rely on contract manufacturing and existing facilities. The high CapEx/Revenue ratios in recent quarters are an artifact of declining revenue rather than increased investment. This implies that the company's cash burn is almost entirely operational, tied to clinical trial costs and headcount, and that future capital needs will likely be for commercial manufacturing scale-up if AXPAXLI is approved.

The working capital line items show no consistent pattern, with both positive and negative swings across quarters. This volatility likely stems from the lumpy nature of clinical trial expenses and milestone payments, as well as the timing of collections from the Regeneron collaboration. The absence of a persistent working capital drag suggests that the company is managing its payables and receivables adequately, but the swings add noise to quarterly cash flow comparisons.

The capital deployment is singularly focused on advancing the pipeline, with zero cash returned to shareholders. This is consistent with a clinical-stage biotech that needs to preserve cash for trials and potential regulatory milestones. The absence of buybacks or dividends is not a concern at this stage, but it underscores that the company's value creation is entirely dependent on successful clinical outcomes, particularly for AXPAXLI.

The cumulative gap between net income and operating cash flow is approximately $154M, driven by significant stock-based compensation and depreciation. This suggests that the company's cash runway is longer than the reported losses imply, but the gap also highlights the dilutive impact of SBC on shareholders. Investors should note that while cash burn is high, it is somewhat lower than the accounting losses, providing a slight cushion to the $737M cash balance.